LICENSE AGREEMENTLicense Agreement • November 9th, 2015 • Aveo Pharmaceuticals Inc • Pharmaceutical preparations • New York
Under the terms of the agreement, Pharmstandard is obligated to pay AVEO an upfront payment of $1.5 million. AVEO is also eligible to receive up to $7.5 million in connection with the first marketing authorization of tivozanib in Russia, $3.0 million for each additional approved indication thereafter and a high single-digit royalty on net sales in the above mentioned territories. Pharmstandard will be responsible for all activities and costs associated with the further development, regulatory filings, health services and commercialization of tivozanib in the specified territories. A percentage of all upfront, milestone and royalty payments received by AVEO are due to Kyowa Hakko Kirin as a sublicensing fee.
LICENSE AGREEMENTLicense Agreement • November 9th, 2015 • Aveo Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
This First Amendment to the Research and Commercialization License Agreement (the “Amendment”) is made and entered into as of September 26, 2012 (the “Amendment Effective Date”), by and between AVEO Pharmaceuticals, Inc. (“AVEO”) and Cephalon Australia (VIC) Pty Ltd., formerly known as EvoGenix Pty Limited (“Ceph Australia”), and upon execution will be incorporated into the Research & Commercialisation Licence Agreement between AVEO and Ceph Australia dated September 25, 2007, and signed September 26, 2007 (the “Agreement”). The terms and provisions of the Agreement are incorporated by reference into this Amendment. Capitalized terms used in this Amendment and not defined shall have the meanings ascribed to them in the Agreement.
ContractLicense Agreement • November 9th, 2015 • Aveo Pharmaceuticals Inc • Pharmaceutical preparations • New South Wales
Amended and Restated License Agreement St Vincent’s Hospital Sydney Limited ABN 77 054 038 872 and AVEO Pharmaceuticals, Inc. Anti MIC-1 antibody for treatment of cachexia, etc. Amended and Restated as of August 13, 2015
